\[Objectives and Background\] Noninvasive ventilation (NIV) is the standard treatment for respiratory failure caused by acute exacerbations of chronic obstructive pulmonary disease (COPD). Numerous recent studies have demonstrated its efficacy, showing improvements in arterial blood gas results, reduced intubation rates, shorter hospital stays, and lower mortality rates.
Some studies suggest that NIV may also be beneficial for patients with stable chronic hypercapnic COPD. Randomized controlled trials (RCTs) have confirmed that applying NIV in these patients reduces one-year mortality, acute exacerbations, and hospital admission rates, while improving hypercapnia, oxygen saturation, respiratory rate, dyspnea, six-minute walk test results, and quality of life. However, some patients have difficulty adapting to NIV, limiting their benefits from the therapy.
High-flow nasal cannula (HFNC) therapy has been developed to deliver heated and humidified air through slightly enlarged nasal prongs. HFNC effectively reduces dead space by rapidly clearing expiratory gas from the upper airway and ensures the delivery of high-flow gas without dilution with ambient air. Studies have shown that HFNC reduces intubation rates and mortality in patients with severe hypoxemic respiratory failure. Compared to NIV, HFNC is not inferior in terms of re-intubation rates. Moreover, HFNC has demonstrated rapid reductions in CO2 levels in hypercapnic patients. Preliminary studies have confirmed its effectiveness in long-term use for patients with stable chronic hypoxemic or hypercapnic respiratory failure, with the most effective flow rates ranging from 30-50 L/min.
This clinical trial aims to compare the effects of NIV and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD. Participants will use each device for six weeks in a crossover design, and the primary outcome will be a comparison of arterial CO2 reduction.
\[Inclusion Criteria, Exclusion Criteria, Target Sample Size, and Rationale\]
1. Inclusion Criteria:
* Adults aged 40 years or older
* Diagnosed with COPD
* Resting arterial blood gas analysis showing pCO2 \> 45 mmHg
* Ability to read and write Korean
* Voluntarily provided written informed consent For elderly patients (≥80 years), if cognitive function or judgment is impaired, informed consent may also be obtained from a legal representative. During the study period, participants will receive device training and explanations in a quiet setting to ensure understanding.
2. Exclusion Criteria:
* Refusal to consent
* Difficulty using NIV or HFNC
* Cognitive impairment preventing understanding of the study
* Acute exacerbation of hypoxemia or hypercapnia within the past four weeks
3. Target Sample Size: 38 Participants
4. Rationale for Sample Size: A previous study confirmed a significant reduction in arterial CO2 levels of 4 mmHg with HFNC compared to standard treatment in stable hypercapnic COPD patients. This study is designed as a non-inferiority crossover trial, with a non-inferiority margin of -4 mmHg, a standard deviation of 6.0 mmHg, a two-sided significance level of 5%, and a power of 80%. Based on these parameters, 34 participants are needed. Allowing for a 10% dropout rate, the final target sample size is set at 38 participants.
\[Study Duration\] From Institutional Review Board (IRB) approval to 18 months thereafter.
\[Study Parameters\]
* Demographics: age, sex, height, weight, body mass index, smoking status (current/ex/non), smoking pack-years
* Arterial blood gas analysis (3 times: baseline, crossover, end of study): pH, PaCO2, PaO2, HCO3-, SPO2
* PtCO2 (transcutaneous CO2)
* Pulmonary function test (within the last year): FEV1 (L), % predicted FEV1, FVC (L), % predicted FVC, FEV1/FVC (%)
* Dyspnea scale: mMRC score
* Home oxygen therapy status and flow rate
* Current treatment medications: inhaled bronchodilators, inhaled corticosteroids
* Average daily usage time
\[Study Methods\] Participants will be randomly assigned to NIV (Trilogy Evo®) or HFNC (myAirvo2®) in a 1:1 ratio for six weeks, then crossover to the alternate device for another six weeks. Assessments will be conducted at baseline (V1), after the first device (V2), and after crossover completion (V3).
